I have a feeling that we will look back on today and say this was a fairly important reversal day, maybe not only in risk assets, but possibly in investor sentiment towards the effectiveness of Central …
Continue readingXBI
To say that market participants are nervous at the moment is a bit of an understatement. Most investors probably can’t even remember the last time the S&P 500 (SPX) was down 9% and the Nasdaq …
Continue readingRegardless of whether you think the bull market that started in Q1 of 2009 is over or not, one thing is fairly certain, that the breadth of the rally in large cap U.S. stocks petered …
Continue readingLast night on CNBC’s Fast Money Meg Tirrell interviewed Merck CEO Ken Frazier. As usual, Meg ran a great interview. Since healthcare related stocks are not my forte I found myself looking down at my Bloomberg …
Continue readingIt’s our view that the rolling sell off in U.S. equities that started this past spring / summer in past bull market darlings Apple (AAPL), Disney (DIS), JP Morgan (JPM), Solar Stocks, Tesla (TSLA), Semiconductors, …
Continue readingEarlier in my opening post (MorningWord 9/28/15: The Investment Landscape Is Moving Beneath Our Feet) I pointed out that if the S&P 500 (SPX) were to retest the October 2014 lows near 1820 (down about 4.25% from current …
Continue readingThere seems to be a growing chorus of market participants and pundits (including moi) that the S&P 500 (SPX) will not only soon break the August 24th panic low of 1867, but also retest the …
Continue readingWhen market participants lack confidence in the underpinnings of the investment environment they quickly turn to technical analysis as their main trading input (there are some traditionalists with a long timer horizon that still view …
Continue readingTwo weeks ago we looked to fade the bounce in the biotech etf XBI with a slightly out of the money put spread. A few things have happened since then that I want to go …
Continue readingYesterday (here) we took another look at the Biotech sector. We first posted feelings on Aug 6th, where we made the following observation from a technical and sentiment standpoint: The M&A frenzy in Biotech is …
Continue reading